Ravulizumab

Efficacy subgroup analyses from the Phase III CHAMPION-NMOSD trial 3:22
Efficacy subgroup analyses from the Phase III CHAMPION-NMOSD trial
Michael Levy • 26 Apr 2023
The future of ravulizumab in NMOSD 1:02
The future of ravulizumab in NMOSD
Michael Levy • 26 Apr 2023
Optimization of myasthenia gravis management: knowledge gaps 3:24
Optimization of myasthenia gravis management: knowledge gaps
James F. Howard Jr. • 12 Apr 2022
Complement inhibitor therapy for myasthenia gravis: current and future outlooks 2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr. • 12 Apr 2022
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis 2:05
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis
James F. Howard Jr. • 12 Apr 2022
The expanding treatment landscape for myasthenia gravis 2:11
The expanding treatment landscape for myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
The content of VJNeurology is intended for healthcare professionals